InflaRx (NASDAQ:IFRX) Short Interest Update

InflaRx (NASDAQ:IFRX) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 241,700 shares, a drop of 8.1% from the September 30th total of 262,900 shares. Based on an average trading volume of 71,800 shares, the short-interest ratio is presently 3.4 days.

InflaRx Stock Performance

Shares of NASDAQ:IFRX traded down $0.02 during trading on Thursday, hitting $1.55. The company’s stock had a trading volume of 88,059 shares, compared to its average volume of 156,252. The company has a market capitalization of $91.27 million, a PE ratio of -1.99 and a beta of 1.57. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $2.10. The stock’s 50-day moving average price is $1.53 and its two-hundred day moving average price is $1.50.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). InflaRx had a negative net margin of 44,046.09% and a negative return on equity of 47.03%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.04 million. On average, equities analysts predict that InflaRx will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in InflaRx stock. Ikarian Capital LLC lifted its position in shares of InflaRx (NASDAQ:IFRX) by 2.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the period. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 42.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research report on Wednesday, September 25th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.